Hypertension is only controlled in approximately 35% of the patients, which could be partially due to nonadherence. Recently, bioanalytical assessment of adherence to blood pressure (BP) lowering drugs has gaining interest. Our aim was to explore possible determinants of nonadherence in treatment resistant hypertension, assessed by objective screening for antihypertensive agents in serum. The secondary aim was to study the effect of adherence on the change in BP.
Introduction
Hypertension, defined as an office systolic blood pressure (SBP) > 140 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, is only controlled in approximately 35% of patients [1, 2] . Worldwide, 874 million adults suffer from an office SBP of 140 mmHg or higher, which is associated with an annual death rate of 106 per 100 000 patients [3] . For the pharmacological control of hypertension, adherence to blood pressure (BP) lowering drugs is essential. Poor adherence is associated with a higher residual cardiovascular risk (for the patient) and a high healthcare burden, due to greater effort to improve BP with additional diagnostic tests and interventions, such as renal denervation (RDN) [4, 5] . Previous cross-sectional studies published information on factors of nonadherence in patients with hypertension [6] [7] [8] [9] [10] . However, almost all studies on adherence in hypertension are based on the self-assessment Morrisky questionnaire; a method shown to overestimate adherence and to be potentially biased. In contrast, the results of objective adherence measurements using drug screening in urine and blood are unbiased. In general, the assessment based on screening in urine provides information on long-term use, whilst detection in serum can be considered indicative of short-term drug intake [11] . From a pharmacological perspective, the latter is more related to BP measurements performed within the same time frame as sample collection [12] .
Unbiased information on adherence is of importance in the decision-making process of the treating physician, an objective tool can be of great importance for example to refine or define treatment-resistant hypertension. Such a diagnostic tool can prevent new invasive treatment options and divert focus towards adherence training. In the present study, we investigated drug adherence through bioanalytical screening for antihypertensive agents in serum and explored the relation between adherence and BP levels over time.
Methods

Study design and study population
The study was designed as a posthoc analysis as part of the SYMPATHY-trial, in which adherence screening in serum was performed [4] . The SYMPATHY-trial is an open-label randomized-controlled trial in which patients were randomized to RDN plus usual care vs. usual care alone (clinicaltrials.gov number: NCT01850901) [13] . Patients were included in SYMPATHY from 14 different secondary and tertiary Dutch centres, from May 2013 to December 2015. Primary endpoint in the trial was BP lowering efficacy of RDN after 6 months. In order to be eligible to participate in this study, a subject had a mean daytime systolic BP ≥ 135 mmHg, as determined with the use of ambulatory BP measurement (ABPM), while having been prescribed three or more antihypertensive agents for at least 3 months prior to inclusion or with documented intolerance to two or more of the four major classes antihypertensive drugs (ace-converting-enzyme/ angiotensin-receptor blocker, calcium channel blocker, β blocker, diuretic) and no possibility to take three antihypertensive drugs. The most important exclusion criteria were a treatable secondary cause of hypertension, an estimated glomerular filtration rate <20 ml min -1 1.73m -2 and an ineligible renal artery anatomy for treatment. The present posthoc analysis on adherence originated from a new research question and permission was granted to use stored blood samples of SYMPATHY patients that gave a broad consent to use their blood for future research. The storage of blood samples was optional for participating centres (appendix, Table 1 ). SYMPATHY and this substudy were approved by the ethical committee of UMC Utrecht.
Adherence assessment
All prescribed medication, including BP lowering drugs, were listed at baseline and 6 months by their generic name, dosage and frequency. BP lowering drugs were identified according to the Anatomical Therapeutic Chemical classification system of the World Health Organization Collaborating Centre for Drug Statistics. In addition, we registered the different classes of prescribed BP lowering drugs. Blood was collected at baseline and 6 months on the same day 24-h ambulatory and office BP measurements were performed and stored as serum at -80°C. Serum screening for BP lowering drugs using liquid chromatography, combined with tandem mass spectrometry (LC-MS/MS) was performed as a batch at the end of the study. Patients and physicians were unaware of the adherence assessment at the time of blood sample collection.
Identification of BP lowering drugs was performed with LC-MS/MS combined with a spectra library search. First, phospholipid removal technology was employed for sample purification and enrichment. After purification, the samples were analysed using LC-MS/MS under full-scan and data-dependent MS/MS mode. The acquired mass spectra were compared with an in-house library (compound library and MS/MS mass spectral library) built with automated screening software (Thermo Fisher Scientific) which contained the mass/charge of the precursor ion, retention time, product ions and the entire MS/MS spectra of 40 compounds including metabolites covering over 95% of all BP lowering drugs registered in The Netherlands. Identification was achieved by comparing full MS/MS spectra and/or mass/charge of precursor ion with confirmation by second selected reaction monitoring transitions. Furthermore, we randomly resampled a batch to test the reproducibility of the method. The analysts that performed LC-MS/MS and interpret the results were unaware of the patients' BP or treatment arm.
Medication adherence was documented in three different categories: adherent (81%-100% match prescribed vs. measured), poorly adherent (1-80% match prescribed vs. measured) and completely nonadherent (0% match prescribed vs. measured) [14] . Change in adherence between baseline and follow-up was categorized as: decrease in adherence (baseline adherence higher than follow-up adherence), stable adherence (baseline adherence equal to follow-up adherence) Table 1 Baseline characteristics of the studied population (n = 98)
Non-adherent
Poorly adherent Adherent n = 16 n = 52 n = 30
Age (years) 57 (13) 65 (9) 63 (11) Sex male* 7 (44) 22 (43) (28) 162 (22) 165 (24) Diastolic (mmHg) 106 (22) 89 (14) 92 (13) Heart rate (bpm) 76 (11) 69 (12) 68 (12) 24-h ABPM Systolic (mmHg) 162 (17) 155 (15) 158 (19) Diastolic (mmHg) 96 (17) 88 (15) 89 (13) Heart rate (bpm) 70 (12) 70 (11) 68 ( and increase in adherence (baseline adherence lower than follow-up adherence).
Physical and biochemical parameters
A detailed description of the collection of physical and biochemical outcome measures has been previously published by our group [13] . In short, office and 24-h BP measurements were performed at baseline and 6 months using recommended devices from the ESH/ESC guidelines and under standardized conditions [15] . Office BP was an average of four BP measurements (two on each arm). ABPMs were considered valid when ≥70% of the recordings was successful. Information on cardiovascular history, smoking, alcohol, duration of hypertension and socio-economic status were collected at baseline. Biochemical parameters as lipid spectrum, and creatinine (and estimated glomerular filtration rate) were assessed at baseline and 6 months follow-up during routine patient care.
Statistical analysis
Due to the posthoc nature of the study a formal sample size calculation was not done in advance. Data were expressed as mean (standard deviation, SD), median (interquartiles) or as percentage (95% confidence interval, CI), unless stated otherwise. Paired t tests were used to compare means within individuals. To explore a relation between patient characteristics and the level of adherence we used a multivariable linear regression model with adherence as dependent variable and the following independent variables, based on literature or hypothesis: baseline office systolic BP, age, sex, duration of hypertension, education, number and type of class of BP lowering pills. A backward model was applied to minimize the chance on suppression of variables [16] . To assess determinants of change in adherence, a similar multivariable linear regression analysis was applied. The treatment to which the patient was assigned in the original study (RDN or usual care) was added to this model. Univariable linear regression analysis was used to analyse the possible relationship between level of adherence and BP. A two-sided 0.05 level of significance was used. Statistical analyses were done using SPSS version 21 (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
Of the 139 patients included in SYMPATHY, 98 patients gave their consent to store blood specimens for future research purposes (Table 1) . Mean age was 63 (standard deviation 11) years and 42% of the study population was male (n = 41). The prevalence of cardiovascular morbidity was 48% (n = 47). The average number of prescribed BP lowering pills was 3.6 (SD 1.4). RAS (renin-angiotensin system)-inhibitors and diuretics were most often prescribed (Table S1 ). Mean office BP was 167 (SD 25) / 92 (SD 16) mmHg and mean 24-h BP was 157 (SD 17) / 90 (SD 15) mmHg. Baseline characteristics of those with adherence measurements did not significantly differ from the original sample of139 patients in SYMPATHY (data not shown) [4] .
Adherence to BP lowering medication
At baseline, 68% (95%CI 59-78) of the patients was nonadherent to their prescribed BP lowering drugs (n = 67). Sixteen patients were completely nonadherent (16%), 51 poorly adherent (52%) and 31adherent (32%; Table 1 ). Overall, of the 3.6 drugs prescribed, 1.5 could be detected in the blood sample (P < 0.001; Table S2 ). In seven patients, more pills were detected than prescribed (Figure 1 ). Adherence at baseline declined significantly with the increase of number Figure 1 Relation between the number of prescribed and the number of detected BP lowering pills in blood at baseline with line of identity (0 = 0, 1 = 1, etc.). One dot represents one patient
Figure 2
Number of patients that was prescribed to different classes of BP lowering drugs and the number of patients in which the prescribed class was detected. BP: blood pressure; RAS: renin-angiotensin system of prescribed drugs ( Figure 1 and Table S3 ): for every one pill more prescribed, 0.785 prescribed pill was less detected in blood (B = 0.785, P < 0.001). Other important determinants for nonadherence at baseline were: higher baseline office SBP (P < 0.001) and younger age (P = 0.082; Table S3 ). Overall, the best adherence was found for RAS-inhibitors and β-blockers (59% and 59% of the adherent patients, respectively) and the worst for calcium antagonists (27% of the patients adherent; Figure 2) . At 6 months, a similar pattern was seen in the 83 patients of whom stored samples were available (data not shown).
Using the described bioanalytical method for the identification of antihypertensive agents in serum a sensitivity of 95%and a specificity of 91% was reached. Reproducibility testing showed identical serum screening results in 49 of 52 samples (93%) of in total 147 analysed compounds.
Adherence and BP
Baseline office and ambulatory BP were the highest in the nonadherent group (Table 1) . Low adherence to BP lowering medication was related to higher baseline BP (Table 2a) . This relationship was the strongest for office BP: for every prescribed yet undetected pill, office BP increased with 4/3 mmHg (P = 0.018 and P = 0.003, respectively). Ambulatory BP increased with 2/2 mmHg (P = 0.152 and P = 0.019, respectively). The same trend was seen for change in adherence after 6 months of follow-up. Office BP showed the largest rise after 6 months with an increase in BP of 4/2 mmHg (P = 0.038 and P = 0.044, respectively) for every prescribed yet undetected antihypertensive agent at 6 months, compared to baseline (Table 2b) .
Change in adherence
Overall, the number of prescribed BP lowering drugs increased significantly with 0.3 pills (P < 0.001) at 6 months. The number of detected drugs increased also with 0.3 pills (P = 0.058; Table S2 ). Of the 27 changes in prescribed drug classes (e.g. diuretic was started or stopped) at 6 months, 19 (70%) were not detected in blood. Notably, prescribed changes in RAS-inhibitors and calcium antagonists were not found (Figure 3) . In the 25 patients with a change in adherence overtime, drug adherence increased in13 (17%) patients and 12 (15%) patients were less adherent (Table S4) .
Discussion
Objective assessment in serum of adherence to BP lowering drugs showed that adherence to BP lowering drugs was poor, with factors related to poor adherence being higher number of prescribed BP lowering pills, higher baseline BP and younger age. When adherence decreased overtime, office BP increased significantly. The present study has three unique features:(i) patients and physicians were unaware of the adherence assessments; (ii) BP lowering drugs were measured objectively in blood at different time-points; and (iii) blood samples were taken synchronously with the BP measurements. This is the first study that bioanalytically confirmed compliance in using serum samples while measuring blood pressure.
Medication adherence has been subject of debate for many years and different approaches have been used to screen drug adherence [17] [18] [19] [20] . The most widely used method is a questionnaire, of which the Morrisky is the best known Table 2a Relation between baseline adherence and baseline blood pressure (BP) Table 2b Relation between change in adherence and change in blood pressure Univariable analyses of the possible relation between baseline adherence and baseline BP (2a) and the relation between change in adherence and change in BP (2b). Example: when there is one prescribed BP lowering pill not detected at baseline, office systolic BP is 3.563 mmHg higher at baseline (4a). Or, when one prescribed pill is less detected at 6 months compared to baseline, office systolic BP increases with 4.081 mmHg at 6 months compared to baseline. ABPM, ambulatory BP measurement.
and used in previous intervention studies with hypertensive patients [21] [22] [23] [24] . Questionnaires are relatively inexpensive and noninvasive. However, they are based on the patients' selfreport of adherence, often leading to overestimation. A small study of 47 patients with apparent treatment resistant hypertension concluded that, based on this questionnaire, 26% patients were nonadherent. However, based on serum screening using a bioanalytical assay, objectively assessed nonadherence was found to be 51% [25] . Furthermore, in recent studies with resistant hypertensive patients the percentage nonadherent patients (defined as taken <80% of the prescribed medication detected in urine and blood) was on average 50% [18, 26, 27] . Here, we report a higher prevalence of almost 70%. The discrepancy could be related to the use of urine samples for the assessment in most of the other studies, which could have led to detection long after drug administration. As half-lives of antihypertensive agents and the amount excreted by the kidneys (unchanged or as metabolite) vary greatly, urine screening results are more difficult to relate to short-term drug intake and concomitant BP [11] . Of note, in one study reporting 50% nonadherence, patients were asked to give informed consent for adherence measurements beforehand, which could theoretically have led to an improvement in adherence [26] .
One of the perceived limitations may be that only part of the study population participated, i.e. those in the centre where storage of blood samples was possible. Nonparticipation was mostly due to logistical reasons and expected to be random, and not selective. Indeed, this notion is confirmed by the fact that baseline characteristics did not differ between these two groups of centres. A second limitation may be that included patients were analysed as one group, despite that part of the group underwent RDN. This may have affected the 6 months results. However, we adjusted these multivariable analyses, by adding intervention as independent variable. Thirdly, the study population was part of a randomized trial, including a more invasive and frequent follow-up, which generally is associated with an increase in adherence [28] . In this case underestimation of nonadherence as opposed to overestimation is expected. Further, we do not know how many participants used fixed-dose combinations. It would be of interest to study the effect of fixed-dose combination treatment on adherence in future trials. Finally, in seven patients, more pills were detected than prescribed. We believe that this finding resembles daily practice (instead of a detection error), as supranormal adherence has been reported to be a common finding [29] . In our study, we considered these patients to be completely adherent.
Our results support that no or poor adherence is related to higher BP, which is also found in previous studies [18, 26, 27, 30] . However, in contrast with earlier studies, in which no relationship was observed between change in adherence and change in BP during follow-up [26, 27] , we found that office BP increased when adherence decreased during follow-up. As this and other studies found especially a low adherence to calcium channel blockers [8, 31] , it is important to evaluate if there are alternatives for this class of BP lowering drug. Tablets with a combination of classes of BP lowering drugs are preferred, since it will increase the adherence. In conclusion, objective methodology, using a bioanalytical screening assay, to assess adherence to BP lowering drugs, provides a valuable tool to define true resistant hypertension and, when applicable, refine a treatment plan in consultation with the patient. 
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Figure 3
The number of patients in which the prescription of BP lowering classes changed at 6 months compared to baseline (e.g. at baseline no diuretics, but, at 6 months, diuretics were prescribed) and the number of patients in which the change in prescription was detected in blood. BP: blood pressure; RAS: renin-angiotensin system
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